Geron Corporation (GERN) appears to have a dramatic 2H 2012 ahead of it with its telomerase inhibitor, Imetelstat, having topline data being released for phase II trials in breast cancer and for multiple myeloma. Telomerase appears to be a good target for attacking cancer because most cancers have high levels of telomerase activity according to the company s website. Adding to the therapy's potential value in fighting cancer in an adjuvant setting with paclitaxel and/or bevacizumab for breast cancer and with/without lenalidomide for multiple myeloma, the drug is also in phase II trials for non-small cell lung cancer and Essential Thrombocythemia (ET) or Polycythemia Vera (PV). However, promising data in preclincals indicating efficacy in inhibiting cancer stem cells (CSC) growth in a broad range of tumors could turn into a huge catalyst in upcoming years. CSC's are thought to be responsible for the recurrent nature and metastasis of many cancers, and solid efficacy in advanced trials could prove to be a significant event as this indication is further investigated.